Decreased Expression of Peroxisome Proliferator-activated Receptor α Gene as an Indicator of Metabolic Disorders in Stunting Toddler

Khairun Nisa Berawi1,2*, Ani Melani Maskoen2, Ieva Akbar1

1Department of Biomolecular, Biochemistry and Physiology, Faculty of Medicine, University of Lampung, Indonesia; 2Molecular Genetics Laboratory, Faculty of Medicine, University of Padjadjaran, West Java, Indonesia; 3Department of Physiology, Faculty of Medicine, University of Islam Bandung, West Java, Indonesia

Abstract

BACKGROUND: Stunting in children increases the risk of degenerative diseases in adulthood, including dyslipidemia, obesity, type 2 diabetes mellitus, and cardiovascular disease. This is based on the result of metabolic changes that may be caused by chronic malnutrition and experienced by stunting children. Stunting in children is associated with metabolic disorders that are based on impaired fat oxidation, a trigger factor for obesity in adulthood. The peroxisome proliferator-activated receptor (PPAR) α gene is a transcriptional factor that regulates fat, carbohydrate, and amino acid metabolism whose genetic variants are linked to the development of dyslipidemia and cardiovascular disease.

AIM: The study assessed the effect of metabolic changes in stunting toddler on PPARα gene expression.

MATERIALS AND METHODS: An analytical-observational laboratory was done using 41 blood samples, coming from 23 stunting toddlers, and 18 not-stunting toddlers. In all research subjects, anthropometric measurements and examination of PPARα gene mRNA expression were carried out. Analysis of PPARα gene mRNA expression using one-step quantitative reverse transcriptase-polymerase chain reaction using specific primers, as a comparison of gene expression using the GAPDH gene. The relative expression of the PPARα mRNA gene was analyzed using the LIVAK formula.

RESULTS: The study obtained a mean of ΔCT in stunting toddlers of 5.81, whereas in stunting toddlers at 5.082. We conclude that there is a decrease in PPARα gene expression in stunting toddlers.

CONCLUSION: We conclude that there is a decrease in PPARα gene expression in stunting toddlers.
the uptake, use, and catabolism of lipid acids by upregulating genes involved in lipid acid transport, binding and activation of lipids, and beta lipid acid oxidation in peroxisomes and mitochondria [18], [19]. The expression of the PPARα gene can be activated by ligand which can be an external/synthetic factor such as dietary intake containing polyunsaturated fatty acids (SFA) and fibrate drugs used for dyslipidemia [13], [15], [16], [17]. Endogenous ligands include fatty acids such as arachidonic acid and their metabolism. Certain nutritional conditions, such as protein restriction diets for a long time (malnutrition), which are found in stunting toddlers, produce long-term effects on PPARα gene expression through modification in the methylation of specific loci surrounding the PPARα gene related to the development of several diseases in the body, such as dyslipidemia, diabetes, and obesity [16], [20], [21], [22], [23]. This proves the PPARα gene as a mediator of metabolic adaptation responses to nutritional and environmental factors [15], [18], [19]. As a transcriptional factor, PPARα refers in transcriptional factors of various regulatory genes that play a role in metabolism such as fatty acid metabolism, bile acid synthesis, synthesis and degradation of ketone objects, and metabolic glycerophospholipid as well as its interaction with various PPAR superfamily genes and core receptors [13], [16], [17], [24], [25].

Research on the relationship of metabolic disorders that occur with stunting children to the expression of PPARα gene which is a mediator metabolic gene for adaptation response to nutritional and environmental factors in Indonesian children, have never been established yet, mainly in 2018 when the research was done.

**Materials and Methods**

This research is an observational laboratory analytic study. The assessment was performed on 41 toddlers with 23 stunting toddlers and 18 toddlers without stunting.

**Anthropometric examination and venous blood extraction**

Venous blood extraction was performed to measure PPARα gene expression and compare the decline between stunting and non-stunting children. Anthropometric measurements using the WHO global database on child growth and malnutrition for a Z score cut off point of <-2 SD to height for age in stunting subject. Not stunting subject if point range between -2 sd to +2 SD [19]

**Examination of PPARα gene by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)**

Analytical-observational laboratory of PPARα gene expression was carried out by examining qPCR (real-time PCR) in blood ethylenediaminetetraacetic acid toddlers. There are four steps that were done, namely, primary design, RNA isolation, NanoDrop, and quantification of gene expression using qPCR.

**The primary design**

This study found that the primary base sequence of the PPARα gene refers to previous research and after checking with BLAST according to the target gene that you want to examine. The primary sequence of the PPARα gene is as follows: [12]

Forward primer: 5'-TGCAGATCTCAAATCTCTGG-3'
Reverse primer: 5'-ATCACAGAAGACAGCATGGC-3'.

**RNA isolation using NanoDrop**

Isolation and measurement of RNA concentration using NanoDrop. RNA was extracted using QIAamp RNA Blood Mini Kit (Qiagen 52304) following the manual kit procedure. The RNA concentration obtained was then measured using a NanoDrop 2000 Spectrophotometer from Thermo Scientific.

**Measurement of PPARα gene expression using qRT-PCR**

Measurement of PPARα gene expression using one-step qRT-PCR. The primers used are as follows: Primary forward: 5'-TGCAGATCTCAAATCTCTGG-3' and primary reverse: 5'-ATCACAGAAGACAGCATGGC-3' [26] 2–10 ul RNA template (sample isolated) added PCR master-mix containing primer. The PCR cycle conditions for genes included an initial denaturation step of 94°C for 3 min, followed by an amplification cycle consisting of denaturation at 94°C for 45 s, annealing at 58°C for 45 s, extension 72°C for 45 s, and final extension at 72°C for 10 min.

The measurement of the PPARα gene concentration is using the relative quantification method. Measuring the cycle threshold of the PPARα gene compared to the GADPH gene as new housekeeping gene and comparing the mean between the two groups and the mean level of decrease in gene expression.

\[
\Delta \Delta C_T = \Delta C_T \text{stunting} - \Delta C_T \text{non stunting}
\]

The comparison of gene expression levels = \(2^{\Delta \Delta C_T}\). The measurement of concentration is by using LightCycler® software program referred to LIVAK formula (concentration in picogram size).
This research has received ethical research approval from the ethics committee of the Faculty of Medicine, University of Lampung in 2018, and in collaboration with the Molecular Genetics Laboratory, Faculty of Medicine, University of Padjadjaran, Bandung, Indonesia.

Results

Sample characteristics

Toddlers are the sample of this study. The research were held with 41 children under five (Tables 1 and 2), consisting 14 boys and 27 girls. Under-five children are aged between 24 months and 60 months, with an average age of 41.85 months. A total of 23 stunting toddlers and 18 children under five were not stunting. They came from one study area in Central Lampung District, Lampung Province. Blood samples were taken from all toddlers in the research subject and then being grouped between stunting toddlers and toddlers not stunting.

Table 1: qPCR optimization of the PPARα gene and the main GADPH for infants who are not stunted by growth

| Subject | CT GADPH | CT PPARα | ∆CT |
|---------|----------|----------|-----|
| A       | 28.28    | 32.68    | 4.4 |
| B       | 27.46    | 31.41    | 3.95|
| C       | 27.61    | 32.24    | 4.63|
| D       | 24.02    | 28.97    | 4.95|
| E       | 30.56    | 35.59    | 6.03|
| F       | 30.08    | 37.97    | 7.88|
| G       | 31.47    | 34.39    | 2.92|
| H       | 30.23    | 34.55    | 4.32|
| I       | 30.12    | 38.54    | 8.42|
| J       | 29.83    | 32.32    | 2.49|
| K       | 29.48    | 34.51    | 5.03|
| L       | 25.61    | 29.07    | 3.46|
| M       | 23.19    | 28.11    | 4.92|
| N       | 27.86    | 33.51    | 5.65|
| O       | 26.75    | 30.39    | 3.64|
| P       | 20.62    | 28.55    | 7.93|
| Q       | 20.62    | 28.55    | 8.57|
| Average |          |          | 5.0 |

Optimization of real-time PCR of PPARα and GADPH genes

The results showed threshold cycle PPARα gene expression (CT PPARα) in non-stunting toddlers with an average (∆CT) of 5.0 (Table 1 and Figure 1).

Figure 1: The main optimization chart of the peroxisome proliferator-activated receptors α gene and GADPH qPCR for toddlers who are not stunted by growth

Figure 2: Quantitative polymerase chain reaction graph primary optimization of the peroxisome proliferator-activated receptors α gene and GADPH stunting toddlers

Decrease expression in PPARα stunting toddlers

The results showed stunting toddlers threshold cycle PPARα gene expression (CT PPARα) in stunting toddlers with a mean (∆CT) of 5.81 compared to non-stunting toddlers of 5.0. For normalization we use hausekeeping genes, the GADPH gene. Comparison of expressions was used to compare groups of toddlers who are not stunting. The measurement results showed that the higher CT is, the lower gene expression was measured, so the difference in threshold cycle average (△△CT) between stunting toddlers and non-stunting toddlers was 0.81, and the PPARα mRNA gene expression based on LIVAK 2 formula ^ - (∆△CT) is 0.6. It means that if there is no change in expression between stunting and non-stunting, the value is 1, while the value obtained is 0.6 means a decrease in expression in non-stunting toddlers.

Table 2: qPCR tables primary optimization of the PPARα gene and GADPH stunting toddlers

| NAMA | CT GADPH | CT PPARα | ∆CT |
|------|----------|----------|-----|
| A    | 22.44    | 30.44    | 8   |
| B    | 20.55    | 27.79    | 7.24|
| C    | 21.74    | 28.35    | 6.61|
| D    | 20.51    | 26.49    | 5.98|
| E    | 23.88    | 29.63    | 5.75|
| F    | 18.79    | 26.92    | 8.13|
| G    | 18.8     | 26.05    | 7.25|
| H    | 27.18    | 31.99    | 4.81|
| J    | 20.34    | 28.5     | 8.16|
| K    | 20.78    | 29.68    | 8.9 |
| L    | 31.52    | 32.79    | 1.27|
| M    | 22.73    | 30.7     | 7.97|
| N    | 32.49    | 33.3     | 0.81|
| O    | 19.49    | 27.23    | 7.74|
| P    | 26.38    | 30.72    | 4.34|
| Q    | 27.18    | 31.99    | 4.81|
| R    | 30.8     | 30.75    | -0.05|
| S    | 29.48    | 34.51    | 5.03|
| T    | 23.19    | 28.11    | 4.92|
| U    | 22.35    | 28.64    | 6.29|
| V    | 25.61    | 29.07    | 3.46|
| W    | 30.08    | 37.97    | 7.89|
| X    | 26.7     | 29.13    | 2.43|
| Average |          |          | 5.817727273 |

PPAR: Peroxisome proliferator-activated receptors, qPCR: Quantitative polymerase chain reaction.
Discussion

Factors that cause stunting are accumulative chronic processes that can occur starting from maternal nutritional factors from before and during pregnancy that affects the growth of children in the fetus (in the womb), infancy and throughout the first 1000 days of life [9]. The state of malnutrition that occurs in women of reproductive age during pregnancy will cause a disruption in fetal growth and development (Fetal Growth Retardation = FGR) which contribute to the occurrence of stunting in childhood. Children who experience stunting are found to have an increased risk of recurrent infectious diseases and an increased risk of metabolic disorders due to impaired energy used by the body of the affected child [6]. Even a number of studies and analysis that have been done previously suggests a relationship between shortness of obesity in childhood and adulthood. The analysis conducted in five countries of Arabian found that short children have a greater risk than children who are not short to fat [3].

The results showed stunting toddlers’ threshold cycle PPARα gene expression (CT PPARα) in stunting toddlers with a mean (ΔCT) of 5.81 compared to non-stunting toddlers of 5.0 as housekeeping genes used the GADPH gene (CT GADPH). Comparison of expressions was used to compare groups of toddlers who are not stunting. The measurement results showed that the higher CT is, the lower gene expression was measured, so the difference in threshold cycle average (ΔΔCT) between stunting toddlers and non-stunting toddlers was 0.81, so the PPARα mRNA gene expression based on LIVAK 2 formula \(^{- (ΔΔCT)}\) is 0.6. This result shows that if there is no change in expression between stunting and non-stunting, the value is 1, while the value obtained is 0.6 means a decrease in the expression of non-stunting toddlers.

The PPARA gene is a transcriptional factor that regulates target gene proteins that are widely expressed in tissues with high levels of beta fatty acid oxidation such as the liver and muscles also regulating the target genes involved in the transport and oxidation of fatty acids. The PPARA gene was activated due to its binding with ligand. Endogenous ligands such as long-chain fatty acids (long-chain fatty acids) from SFA, unsaturated fatty acids, and eicosanoids, or exogenous ligands of hypolipidemic drugs such as fibrates, fenofibrates, and NSAIDs can even be both [4], [8] (Alsaleh et al., 2012). The expression of the PPAR-α gene induces the expression of lipoprotein lipase, which releases fatty acids from triglycerides and blocks ApoC-III, a LPL inhibitor which decreases triglyceride synthesis. PPAR-α expression also plays a role in limiting the vascular cell inflammatory response through inhibition of the expression of adhesion molecules and limiting the initial inflammatory mediators such as NF-kB and cytokine expression so that it will have an atheroprotective effect in normal condition. Decreasing of PPAR gene expression in stunting children will develop metabolic disorders, including dyslipidemia, atherosclerosis, and diabetes mellitus in adulthood.

Conclusion

The results showed a decrease in PPARα gene expression in stunting toddlers. PPAR-α gene expression takes a role in limiting the vascular cell inflammatory response through inhibition of the expression of adhesive molecules and limiting the initial inflammatory mediators such as NF-kB and cytokine expression so that it will have an atheroprotective effect in normal condition. Decreasing of PPARα gene expression in stunting children will develop metabolic disorders, including dyslipidemia, atherosclerosis, and diabetes mellitus in adulthood.

Acknowledgment

This research was supported by the grant of Research Grants and Community Services in Medical Faculty 2018 Programmed, skim of “Penelitian Unggulan,” University of Lampung, Bandar Lampung, Lampung, Indonesia. Thanks for Chancellor of the University of Lampung, Indonesia.

Declaration

Ethics approval and consent to participate: Ethical approval was given by the Health Research Ethics Committee of Lampung University Medical School with the number No. 3698/UN26.18/PP/05.02.00/2018.

Authors’ contributions

KNB and AMM contributed equally to this work. KNB carried out the molecular genetic studies and
drafted the manuscript. AMM carried out the molecular genetic studies and also in the sequential alignment. IBA participated in the design of the study and performed the statistical analysis and participated in its design and coordination and also helped to draft the manuscript. All authors read and approved the final manuscript.

References

1. de Onis M, Branca F. Childhood stunting: A global perspective. Matern child Nutr. 2016;12(1):12-26. https://doi.org/10.1111/mcn.12231
PMid:27187907

2. Christian P, Lee SE, Angel MD, Adair LS, Arifeen SE, Ashorn P, et al. Risk of childhood undernutrition related to small-for-gestational age and preterm birth in low-and-middle-income countries. Int J Epidemiol. 2013;42(5):1340-55.
PMid:23920141

3. Danaei G, Andrews KG, Sudfeld CR, Fink G, McCoy DC, Peet E, et al. Risk factors for childhood stunting in 137 developing countries: A comparative risk assessment analysis at global, regional, and country levels. PLoS Med. 2016;13(11):e1002164. https://doi.org/10.1371/journal.pmed.1002164
PMid:27802277

4. Lee AC, Katz J, Blencowe H, Cousens S, Kozuki N, Vogel JP, et al. National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. Lancet Glob Health. 2013;1(1):e26 36. https://doi.org/10.1016/s2214-109x(13)70006-8
PMid:25103583

5. Webb AL, Manji K, Fawzi WW, Villamor E. Time-independent maternal and infant factors and time-dependent infant morbidities including HIV infection, contribute to infant growth faltering during the first 2 years of life. J Trop Pediatr. 2009;55(2):83-90. https://doi.org/10.1093/heapro/dfm068
PMid:18723575

6. Wang H, Liddell CA, Coates MM, Mooney MD, Levitz CE, Schumacher AE. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: A systematic analysis for the global burden of disease study 2013. Lancet. 2014;384(9947):957-79.
PMid:24797572

7. Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, et al. Maternal and child undernutrition: Global and regional exposures and health consequences. Lancet. 2008;371(9608):243-60. https://doi.org/10.1016/s0140-6736(07)61690-0
PMid:18207566

8. Hossain M, Choudhury N, Abdullah KA, Mondal P, Jackson AA, Watson J, et al. Evidence-based approaches to childhood stunting in low and middle-income countries: A systematic review. Arch Dis Child. 2017;102(10):903-9. https://doi.org/10.1136/archdischild-2016-311050
PMid:28468870

9. Berawi KN, Hidayati MN, Susianti S, Perdami RR, Susantiningsih T, Maskoen AM. Decreasing zinc levels in stunting toddlers in lampung province, Indonesia. Biomed Pharmacol J. 2019;12(1):239-43. https://doi.org/10.13005/bpj/1633

10. El Taguri A, Betilmal I, Mahmud SM, Monem AA, Goulet O, Galan P, et al. Risk factors for stunting among under-fives in Libya. Public Health Nutr. 2009;12(8):1141-9. https://doi.org/10.1017/s136898000803716
PMid:18789172

11. Mcardle H, Laura A, Wyness A, Gambling L. Normal Growth and Development in Nutrition and Development: Short and Long Term Consequences for Health. Hoboken: British Nutrition Foundation, Wiley-Blackwell; 2013. https://doi.org/10.1002/9781118782972

12. Ikeda N, Irie Y, Shibuya K. Determinants of reduced child stunting in Cambodia: Analysis of pooled data from three demographic and health surveys. Bull World Health Organ. 2013;91(5):341-9. https://doi.org/10.2471/blt.12.113381
PMid:23678197

13. Rakshandehroo M, Knoch B, Müller K, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010;2010:612089. https://doi.org/10.1155/2010/612089
PMid:20936127

14. Rolfe ED, de Franca G, Vianna CA, Gigante DP, Miranda JJ, Yudkin JS, et al. Associations of stunting in early childhood with cardiometabolic risk factors in adulthood. PLoS One. 2018;13(4):e0192196. https://doi.org/10.1371/journal.pone.0192196
PMid:29641597

15. Alsaleh A, Sanders TA, O’Dell SD. Effect of interaction between PPARG, PPARA and ADIPOQ gene variants and dietary fatty acids on plasma lipid profile and adiponectin concentration in a large intervention study. Proc Nutr Soc. 2012;71(1):141-53. https://doi.org/10.1017/jn.2012.473
PMid:22040870

16. Tai ES, Corella D, Deissie S, Cupples LA, Coltell O, Schaefer EJ, et al. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the framingham heart study. J Nutr. 2005;135:397-403. https://doi.org/10.1093/jn/135.3.397

17. Kidani Y, Bentinger S.J, LXR and PPAR as integrators of lipid homeostasis and immunity. Immunol Rev. 2014;249(1):72-83. https://doi.org/10.1111/imr.12284
PMid:22889216

18. Contreras AV, Torres N, Tovar AR. PPAR-α as a key nutritional and environmental sensor for metabolic adaptation. Adv Nutr. 2013;4(4):439-52. https://doi.org/10.1093/advnut/nmt049
PMid:23858092

19. Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care. 2011;34(9):2008 14. https://doi.org/10.2337/dc11-0093
PMid:21816979

20. Delerive P, De Bosscher K, Besnard S, Berghe WV, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274(45):32048-54. https://doi.org/10.1074/jbc.274.45.32048
PMid:10542237

21. Blaschke F, Takai Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in Type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006;26(1):28-40. https://doi.org/10.1161/01.atv.0000191663.12164.77
PMid:16239592

22. Azhar S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010;6(5):657-91. https://doi.org/10.2217/fca.10.86
PMid:2002164

23. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10(3):245-57. https://doi.org/10.1097/00008561-199905000-00001

Open Access Maced J Med Sci. 2020 Apr 15; 8(A):175-180. 179
24. Robitaille J, Brouillette C, Houde A, Lemieux S, Perusse L, Tchernof A, et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet. 2004;49:482-9. https://doi.org/10.1007/s10038-004-0177-9 PMid:15309680

25. Fruchart JC. Selective peroxisome proliferator-activated receptor α modulators (SPPARMs): The next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol. 2013;12:82. https://doi.org/10.1186/1475-2840-12-82 PMid:23721199

26. Dong K, Zhang MX, Liu Y, Su XL, Chen B, Zhang XL. Peroxisome Proliferator-activated receptor alpha expression changes in human pregnant myometrium. Reprod Sci. 2013;20(6):654-60. https://doi.org/10.1177/1933719112461187 PMid:23144166